Complete financial analysis of Reunion Neuroscience Inc. (REUN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reunion Neuroscience Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ITM Power Plc (IJ8.DE) Income Statement Analysis – Financial Results
- EC Healthcare (2138.HK) Income Statement Analysis – Financial Results
- Realord Group Holdings Limited (1196.HK) Income Statement Analysis – Financial Results
- Scotgold Resources Limited (SGZ.L) Income Statement Analysis – Financial Results
- Shenzhen Universe Group Co., Ltd. (000023.SZ) Income Statement Analysis – Financial Results
Reunion Neuroscience Inc. (REUN)
About Reunion Neuroscience Inc.
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 4.86M | 960.90K | 1.00K |
| Cost of Revenue | 0.00 | 9.15M | 1.54M | 9.40K |
| Gross Profit | 0.00 | -4.29M | -583.43K | -8.40K |
| Gross Profit Ratio | 0.00% | -88.27% | -60.72% | -840.30% |
| Research & Development | 12.98M | 7.31M | 3.42M | 193.19K |
| General & Administrative | 12.96M | 34.48M | 12.06M | 2.63M |
| Selling & Marketing | 0.00 | 3.23M | 1.63M | 305.71K |
| SG&A | 12.96M | 37.72M | 13.69M | 2.93M |
| Other Expenses | 2.02M | 3.71M | 1.34M | 139.98K |
| Operating Expenses | 27.96M | 48.74M | 18.45M | 3.27M |
| Cost & Expenses | 27.96M | 57.89M | 19.99M | 3.28M |
| Interest Income | 691.79K | 425.90K | 51.04K | 2.66K |
| Interest Expense | 17.73M | 1.10M | 303.30K | 22.56K |
| Depreciation & Amortization | 3.23M | 3.60M | 1.39M | 146.32K |
| EBITDA | -17.15M | -49.00M | -17.58M | -3.13M |
| EBITDA Ratio | 0.00% | -1,008.13% | -1,829.88% | -312,585.70% |
| Operating Income | -20.37M | -52.60M | -18.98M | -3.27M |
| Operating Income Ratio | 0.00% | -1,082.27% | -1,974.99% | -327,217.70% |
| Total Other Income/Expenses | -17.73M | 14.50M | -4.14M | 643.85K |
| Income Before Tax | -38.10M | -54.69M | -23.12M | -2.63M |
| Income Before Tax Ratio | 0.00% | -1,125.30% | -2,405.84% | -262,832.40% |
| Income Tax Expense | 28.12M | 1.10M | 303.30K | 22.56K |
| Net Income | -66.22M | -55.79M | -23.42M | -2.65M |
| Net Income Ratio | 0.00% | -1,147.86% | -2,437.41% | -265,088.60% |
| EPS | -5.69 | -4.83 | -3.54 | -0.35 |
| EPS Diluted | -5.69 | -4.83 | -3.54 | -0.35 |
| Weighted Avg Shares Out | 11.64M | 11.55M | 6.61M | 7.60M |
| Weighted Avg Shares Out (Dil) | 11.64M | 11.55M | 6.61M | 7.60M |
Field Trip Health Announces Voting Results From the Annual General and Special Meeting of Shareholders
TORONTO, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), today announced the voting results from its Annual General and Special Meeting of Shareholders held on Friday, September 24, 2021. A total of 59.09%...
Field Trip Health Ltd. to Participate in Four Investor Conferences in September
TORONTO, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, today announced it will participate in the H.C. Wainwright 23rd Annual Global...
Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104
Anita H. Clayton, MD, joins Scientific Advisory Board Anita H. Clayton, MD, joins Scientific Advisory Board
Time to Buy the Magic Stocks? Magic Mushrooms, That Is.
The first state to legalize cannabis for medical use was California, in 1996. In 2001, medical marijuana was approved in Canada.
Field Trip Stock Could Climb 300% In One Year
On Wednesday, HC WainWright began coverage of Field Trip Health (NASDAQ:FTRP), a company in the psychedelics space, which is developing a chain of psychedelics-assisted therapy clinics throughout North America and Europe. The firm gave Field Trip a Buy rating and a $20...
Why Field Trip Health Shares Are Trading Higher Today
Field Trip Health (NSADAQ: FTRP) shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $20 price target. The firm said it finds the company's valuation 'compelling' ahead of the...
Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling Independent Psychedelic Therapists To Practice At Its Field Trip Health Centers; Also Launches Training Programs To Educate A New Generation Of Psychedelic Clinicians
TORONTO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce the launch of “KAP Co-op”, a program that...
Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results
TORONTO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported its fiscal first quarter 2022 results for the three months ended...
Source: https://incomestatements.info
Category: Stock Reports